Mallinckrodt Enrolls First Patient in Phase 1 Study of ExpressGraft(TM)C9T1 Skin Tissue

Study of Genetically Engineered Human Skin Substitute to Assess Safety and Tolerability in the Treatment of Diabetic Foot Ulcers

STAINES-UPON-THAMES, United Kingdom, Feb. 14, 2018 -- (Healthcare Sales & Marketing Network) -- Mallinckrodt plc (NYSE: MNK... Devices, Wound Care Mallinckrodt plc, ExpressGraft-C9T1, diabetic foot ulcers

Source: HSMN NewsFeed - February 14, 2018 Category: Pharmaceuticals Source Type: news